Emm, a UK-based femtech innovator, just closed a $9 million seed funding round. Lunar Ventures spearheaded the financing effort, signaling strong investor confidence in connected women's health hardware.
Founder Jenny Button conceived of the device during the pandemic, recognizing a data gap compared to other personal wearables like Oura or Whoop. She noted the absurdity of tracking general wellness without detailed insight into menstrual and reproductive cycles.
This fresh capital fuels the final push toward the product’s official launch scheduled for 2026. The device operates as a standard menstrual cup but integrates ultra-thin, medical-grade silicone sensors.
These embedded sensors capture crucial physiological data throughout the cycle. Button intends this objective data to transform research, diagnosis, and subsequent treatment protocols for reproductive conditions.
Menstrual blood offers unique biomarkers often overlooked in circulatory blood testing. This insight is particularly vital for conditions like endometriosis, which frequently suffers from long diagnostic delays.
The daily brief
Get the free daily brief with the day's AI news, new AI startups and funding rounds every morning.
Join 64,000 other subscribers.
Button highlighted that reproductive health issues affect one in three women severely, often taking seven to ten years to properly diagnose. She asserts the lack of reliable, objective tracking tools has historically hampered clinical understanding.
The company plans an initial market entry into the UK next year, leveraging a waitlist that already surpasses 30,000 pre-orders. Alumni Ventures and BlueLion Global also participated in the strategic funding round.
Future plans include expansion into the competitive U.S. market by early 2027. Furthermore, Emm sees menstrual tracking as just the starting point for broader digital health tools and potential therapeutics.
The company emphasizes stringent data privacy, confirming that user information within the companion app remains encrypted and anonymized or pseudonymized by default. This focus on security is paramount for sensitive health data.
